The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use at 10 µg/mg of lysate.
Is unsuitable for WB.
Binds RNA in vitro. May be involved in RNA metabolism. The expansion of the polyglutamine tract may alter this function.
Widely expressed throughout the body.
Involvement in disease
Defects in ATXN1 are the cause of spinocerebellar ataxia type 1 (SCA1) [MIM:164400]; also known as olivopontocerebellar atrophy I (OPCA I or OPCA1). Spinocerebellar ataxia is a clinically and genetically heterogeneous group of cerebellar disorders. Patients show progressive incoordination of gait and often poor coordination of hands, speech and eye movements, due to cerebellum degeneration with variable involvement of the brainstem and spinal cord. SCA1 belongs to the autosomal dominant cerebellar ataxias type I (ADCA I) which are characterized by cerebellar ataxia in combination with additional clinical features like optic atrophy, ophthalmoplegia, bulbar and extrapyramidal signs, peripheral neuropathy and dementia. SCA1 is caused by expansion of a CAG repeat in the coding region of ATXN1. Longer expansions result in earlier onset and more severe clinical manifestations of the disease.
Belongs to the ATXN1 family. Contains 1 AXH domain.
The AXH domain is required for interaction with CIC.
Phosphorylation at Ser-775 increases the pathogenicity of proteins with an expanded polyglutamine tract. Sumoylation is dependent on nuclear localization and phosphorylation at Ser-775. It is reduced in the presence of an expanded polyglutamine tract.
Cytoplasm. Nucleus. Colocalizes with USP7 in the nucleus.
Detection of Ataxin 1 in Immunoprecipitates of HeLa whole cell lysate (1 mg for IP, 20% of IP loaded) using ab114045 at 10 µg/mg lysate for IP. An anti-Ataxin 1 antibody which recognizes a downstream epitope was used at 1 µg/ml for subsequent western blot detection. Detection: Chemiluminescence with exposure time of 3 seconds.